tradmap

DMRA Financials Damora Therapeutics, Inc.

7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Revenue & net income
-$210M -$105M $0 2019 2020 2021 2022 2023 2024 2025
RevenueNet income
Margins (gross / operating / net)
0% 50% 100% 2019 2020 2021 2022 2023 2024 2025
GrossOperatingNet
Free cash flow (CFO − capex)
-$53M -$26M $0 2019 2020 2021 2022 2023 2024 2025
Free cash flow
Cash vs total debt
$0 $129M $258M 2019 2020 2021 2022 2023 2024 2025
CashTotal debt
Cash flow: operating / investing / financing
-$52M $107M $267M $0 2019 2020 2021 2022 2023 2024 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 -$210M $258M
2024 -$21M $14M
2023 -$38M $21M
2022 -$62M -$43M $33M
2021 -$52M -$53M $63M
2020 -$35M $164M
2019 -$37M $11M

Frequently asked questions

Is DMRA growing its revenue and profit?

See the revenue and net-income charts above for Damora Therapeutics, Inc.'s multi-year trend.

How much debt does DMRA have?

As of FY2025, Damora Therapeutics, Inc. reported — of total debt against $258M of cash.

What is DMRA's profit margin?

In FY2025, gross margin was —, operating margin —, and net margin —.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.